With experienced practitioners knowledgeable across a multitude of different therapeutic areas, technologies and approaches, our senior professionals have helped emerging and mid-size companies, venture capital firms, research institutions, academia and nonprofit advocacy groups thrive and grow.
Linnden Communication’s senior practitioners have extensive experience planning and executing strategic communications across the gamut of life science needs to elevate organization’s visibility with influential target audiences, including:
STRATEGIC
COUNSEL
Messaging / positioning, communications plans, crisis management, spokesperson coaching
THOUGHT
LEADERSHIP
Speaking engagements, scientific awareness, awards, opinion pieces, community relations
Media
Relations
Publicity across scientific, trade, and mass media outlets, media training
Investor
Relations
Financing/IPO support, investor decks, disclosure guidance, quarterly releases
content
production
Press releases, website, backgrounders, fact sheets, contributed articles, editorial content
social
media
Full range of integrated multimedia support across channels
Graphics/
Visuals
Branding, logos, website design, presentations, infographics, marketing materials
Linnden Communication’s team of experts has extensive experience leading communications efforts for some of the largest life science organizations, media outlets, PR agencies and academic institutions. Our practitioners have an average of 20+ years of industry experience as communications and PR professionals which we are happy to share with our clients.
- Company launches
- Run-up to IPO
- Venture investment and public financings
- Collaborations and partnerships
- Product launches and updates
- Executive leadership changes and advisory board updates
- Initiation of clinical trials
- Clinical data readouts
- Scientific publications/presentations
- Facility openings/ribbon cuttings
- Trade shows and speaking engagements
- Repositioning
- Crises and issues
Linnden Communication’s seasoned professionals have been on all sides of the table in life science communications efforts, whether in agencies, as reporters being pitched, in-house practitioners working with outside agencies, or academics and non-profits collaborating with industry.
We understand the challenges of small life science organizations and are ready to serve as your affordable, experienced in-house communications team, and for larger companies we can jump in at a minute’s notice to lend a hand to an existing in-house communications team with specific areas of need.
We don’t have junior staff running your program, monthly retainers, or big agency pricing – and timelines – that could slow your growth. Through years of experience, Linnden team members have gained the trust of and developed strong relationships with media, investors and other key constituents in the life science industry. We’re a flexible, dynamic senior team with a strong track record of delivering cost-effective and high value communications solutions.
BBC: The mystery of the human genome’s dark matter
BioCentury: Making Mubadala Capital Ventures
BioPharma Dive: Bioluminescence Ventures debuts with $477M to speed up drug discovery
BioWorld: Dewpoint and Chemify partner on molecules targeting condensates in oncology and neurodegeneration
Biospace: Lilly, Haya Ink Potential $1B Drug Discovery Deal to Target Obesity and Metabolic Conditions
Chemical & Engineering News: AI is coming. Is the chemistry world ready?
Genetic Engineering News: AACR 2024: EpiBiologics Advances Degraders of Membrane-Bound Proteins
Inside Precision Medicine: Atomic AI’s Large Language Model Employs Chemical Mapping Data to Optimize RNA Therapies
Nature: Editor’s Pick: Atomic AI
Neurology Live: Patient Dosing Underway for Phase 2 Study of RNA Aptamer BB-031 in Acute Ischemic Stroke
PharmaVoice: In biotech’s new market normal, here’s what’s catching this investor’s eye
San Francisco Business Times: Even during biotech down cycle, nearly two dozen Bay Area companies flock to major convention
STAT: Life science investors close nearly $6 billion in new funds
Venture Capital Journal: Bioluminescence Ventures Taps Murray as senior partner
Wall Street Journal Pro Venture Capital: Eli Lily, HAYA, deal targets potential of the ‘Dark Genome’
Blog: GC Therapeutics: A New Era for Plug-and-Play Cell Therapies
Podcast: Raphael Townshend: How AI and RNA Tech is Transforming Drug Discovery (Inside Atomic AI)
Contributed article: The evolution of the RNA therapeutics landscape
Opinion piece: Rethinking Pharma and Biotech Outsourcing
Webinar: The Intersection of Chemistry, Robotics, and AI in Drug Discovery
Speaking engagement: New Tools, New Times: Chemical and Structural AI for Drug Discovery
Speaking engagement: Targeting the Brain: How Biotech is Uncovering the Biology of Brain Disease for Precision Neurotherapeutics
Podcast: Innovative Therapies to Address Unmet Needs in Acute Ischemic Stroke: Shahid Nimjee, MD, PhD
Speaking engagement: CNS Summit
Award: Biocom California 2023 Catalyst Awards
Contributed article: Junk DNA: How the dark genome is changing RNA therapies
Opinion piece: Opinion: The Potential of Neurofilament Light Chain as a Biomarker in Parkinson’s Disease